ImpriMed

ImpriMed is a biotechnology company that uses artificial intelligence to help healthcare providers predict drug responses for cancer patients

Headquarters

Year Founded

Search Tags

AI Cancer Treatment for Dogs, Personalized Medicine for Pets, Canine Chemotherapy Predictions

About Us

ImpriMed uses artificial intelligence to predict the effectiveness of anticancer drugs for dogs with lymphoma or leukemia. By analyzing live cancer cells, they provide personalized treatment options, helping veterinarians choose the most effective chemotherapy for each dog.

Trending Companies

Latest Articles

Medicare will pilot AI-driven prior authorization in 2026 across six states, targeting high-risk services while clinicians make final decisions.

AI-Powered Prior Authorization Comes to Traditional Medicare

Traditional Medicare will pilot AI-assisted prior authorization in 2026 across six states, focusing on high-risk outpatient services. Clinicians retain final say, but incentives and access concerns loom as CMS tests fraud reduction and “gold card” exemptions. Here’s what providers and patients should know.